Literature DB >> 15878356

Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells.

Ya-Ling Hsu1, Po-Lin Kuo, Chun-Ching Lin.   

Abstract

Isoliquiritigenin (ISL) is a natural pigment with the simple chalcone structure 4,2',4'-trihydroxychalcone. In this study, we report ISL induced inhibition in the proliferation of human hepatoma cells (Hep G2) for the first time. The cell proliferation inhibition achieved by ISL treatment resulted in a G2/M-phase arrest and programmed cell death. ISL treatment was found to result in the upregulation of p53, p21/WAF1, Fas/APO-1 receptor, Fas ligand, Bax and NOXA, but not in Bad. To elevate the role of p53 in these functions, we generated Hep G2 cells that express the dominant negative p53, which blocks the transcriptional activity of p53. The enhancement of p21/WAF1, Fas/APO-1, Bax and NOXA were decreased in Hep G2 cells that lack functional p53. Furthermore, Hep G2 cells were significantly more resistant to ISL when the activity of p53 was blocked. These results demonstrated that ISL-inducible p53 plays a key apoptotic role, and may do so by regulating the expression of specific target molecules that promotes efficient apoptotic cell death following G2/M-cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878356     DOI: 10.1016/j.lfs.2004.09.047

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  20 in total

1.  Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.

Authors:  Sung Keun Jung; Mee-Hyun Lee; Do Young Lim; Jong Eun Kim; Puja Singh; Sung-Young Lee; Chul-Ho Jeong; Tae-Gyu Lim; Hanyong Chen; Young-In Chi; Joydeb Kumar Kundu; Nam Hyouck Lee; Charles C Lee; Yong-Yeon Cho; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

2.  Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling.

Authors:  Xiangzheng Chen; Yangping Wu; Yangfu Jiang; Yan Zhou; Yuxi Wang; Yuqin Yao; Cheng Yi; Lantu Gou; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

Review 3.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

4.  Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells.

Authors:  Tatsushi Yoshida; Mano Horinaka; Mami Takara; Mayuko Tsuchihashi; Nobuhiro Mukai; Miki Wakada; Toshiyuki Sakai
Journal:  Environ Health Prev Med       Date:  2008-07-31       Impact factor: 3.674

5.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

6.  Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.

Authors:  Mahmoud Youns; Yu-Jie Fu; Yuan-Gang Zu; Anne Kramer; V Badireenath Konkimalla; Bernhard Radlwimmer; Holger Sültmann; Thomas Efferth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-29       Impact factor: 3.000

Review 7.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

8.  Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell.

Authors:  Kathy Ka-Wai Auyeung; Joshua Ka-Shun Ko
Journal:  Invest New Drugs       Date:  2009-01-13       Impact factor: 3.850

9.  An update on antitumor activity of naturally occurring chalcones.

Authors:  En-Hui Zhang; Ru-Feng Wang; Shu-Zhen Guo; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

Review 10.  Apoptosis inducers in chronic lymphocytic leukemia.

Authors:  Christian Billard
Journal:  Oncotarget       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.